Kymera Therapeutics Inc. (NASDAQ: KYMR) is considered one of the best high-beta stocks to buy now, with an optimistic outlook and confidence in achieving key clinical endpoints and biomarker data. The company recently presented at Citi’s ‘Biopharma Back to School’ Conference, highlighting progress in its targeted protein degradation platform. Kymera Therapeutics Inc. is developing oral TPD drugs that offer greater accessibility and convenience compared to injectable options, working on a broad pipeline with partners like Sanofi. Analysts are bullish on the company, with a consensus Buy rating and a price target implying over 55% potential upside.

Read more at Yahoo Finance: Why Kymera (KYMR) Could Be One of Biotech’s Most Interesting Growth Stories?